CovidFranceV1, Main, Exploration, bibRecord, 000C18

Issues for the management of people with diabetes and COVID-19 in ICU.

Identifieur interne : 000C18 ( Main/Exploration ); précédent : 000C17; suivant : 000C19

Issues for the management of people with diabetes and COVID-19 in ICU.

Auteurs : Antonio Ceriello [Italie] ; Eberhard Standl [Allemagne] ; Doina Catrinoiu [Roumanie] ; Baruch Itzhak [Israël] ; Nebojsa M. Lalic [Serbie] ; Dario Rahelic [Croatie] ; Oliver Schnell [Allemagne] ; Jan Škrha [République tchèque] ; Paul Valensi [France]

Source :

Cardiovascular diabetology [ 1475-2840 ] ; 2020.

RBID : pubmed:32690029

Descripteurs français

KwdFr :
- Antihypertenseurs (usage thérapeutique), Appréciation des risques (MeSH), Betacoronavirus (pathogénicité), Diabète (diagnostic), Diabète (mortalité), Diabète (sang), Diabète (traitement médicamenteux), Dyslipidémies (mortalité), Dyslipidémies (traitement médicamenteux), Facteurs de risque (MeSH), Glycémie (effets des médicaments et des substances chimiques), Glycémie (métabolisme), Humains (MeSH), Hypertension artérielle (mortalité), Hypertension artérielle (traitement médicamenteux), Hypoglycémiants (effets indésirables), Hypoglycémiants (usage thérapeutique), Infections à coronavirus (diagnostic), Infections à coronavirus (mortalité), Infections à coronavirus (thérapie), Infections à coronavirus (virologie), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Interactions hôte-pathogène (MeSH), Marqueurs biologiques (sang), Pandémies (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (mortalité), Pneumopathie virale (thérapie), Pneumopathie virale (virologie), Résultat thérapeutique (MeSH), Unités de soins intensifs (MeSH).
MESH :
- diagnostic : Diabète, Infections à coronavirus, Pneumopathie virale.
- effets des médicaments et des substances chimiques : Glycémie.
- effets indésirables : Hypoglycémiants.
- mortalité : Diabète, Dyslipidémies, Hypertension artérielle, Infections à coronavirus, Pneumopathie virale.
- métabolisme : Glycémie.
- pathogénicité : Betacoronavirus.
- sang : Diabète, Marqueurs biologiques.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Diabète, Dyslipidémies, Hypertension artérielle.
- usage thérapeutique : Antihypertenseurs, Hypoglycémiants, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Appréciation des risques, Facteurs de risque, Humains, Interactions hôte-pathogène, Pandémies, Résultat thérapeutique, Unités de soins intensifs.

English descriptors

KwdEn :
- Antihypertensive Agents (therapeutic use), Betacoronavirus (pathogenicity), Biomarkers (blood), Blood Glucose (drug effects), Blood Glucose (metabolism), Coronavirus Infections (diagnosis), Coronavirus Infections (mortality), Coronavirus Infections (therapy), Coronavirus Infections (virology), Diabetes Mellitus (blood), Diabetes Mellitus (diagnosis), Diabetes Mellitus (drug therapy), Diabetes Mellitus (mortality), Dyslipidemias (drug therapy), Dyslipidemias (mortality), Host-Pathogen Interactions (MeSH), Humans (MeSH), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Hypertension (drug therapy), Hypertension (mortality), Hypoglycemic Agents (adverse effects), Hypoglycemic Agents (therapeutic use), Intensive Care Units (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (mortality), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), Risk Assessment (MeSH), Risk Factors (MeSH), Treatment Outcome (MeSH).
MESH :
- chemical , adverse effects : Hypoglycemic Agents.
- chemical , blood : Biomarkers.
- chemical , drug effects : Blood Glucose.
- chemical , metabolism : Blood Glucose.
- chemical , therapeutic use : Antihypertensive Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypoglycemic Agents.
- blood : Diabetes Mellitus.
- diagnosis : Coronavirus Infections, Diabetes Mellitus, Pneumonia, Viral.
- drug therapy : Diabetes Mellitus, Dyslipidemias, Hypertension.
- mortality : Coronavirus Infections, Diabetes Mellitus, Dyslipidemias, Hypertension, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Host-Pathogen Interactions, Humans, Intensive Care Units, Pandemics, Risk Assessment, Risk Factors, Treatment Outcome.

Abstract

In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.

DOI: 10.1186/s12933-020-01089-2
PubMed: 32690029
PubMed Central: PMC7370631

Affiliations:

Allemagne, Croatie, France, Israël, Italie, Roumanie, République tchèque, Serbie
Bavière, Bohême centrale, District de Haute-Bavière, Lombardie
Milan, Munich, Prague

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000891
to stream Main, to step Curation: 000891

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Issues for the management of people with diabetes and COVID-19 in ICU.</title>
<author><name sortKey="Ceriello, Antonio" sort="Ceriello, Antonio" uniqKey="Ceriello A" first="Antonio" last="Ceriello">Antonio Ceriello</name>
<affiliation wicri:level="3"><nlm:affiliation>IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy. antonio.ceriello@hotmail.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Standl, Eberhard" sort="Standl, Eberhard" uniqKey="Standl E" first="Eberhard" last="Standl">Eberhard Standl</name>
<affiliation wicri:level="3"><nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Catrinoiu, Doina" sort="Catrinoiu, Doina" uniqKey="Catrinoiu D" first="Doina" last="Catrinoiu">Doina Catrinoiu</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta</wicri:regionArea>
<wicri:noRegion>Constanta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Itzhak, Baruch" sort="Itzhak, Baruch" uniqKey="Itzhak B" first="Baruch" last="Itzhak">Baruch Itzhak</name>
<affiliation wicri:level="1"><nlm:affiliation>Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Clalit Health Services and Technion Faculty of Medicine, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojsa M" last="Lalic">Nebojsa M. Lalic</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade</wicri:regionArea>
<wicri:noRegion>Belgrade</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
<affiliation wicri:level="1"><nlm:affiliation>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Zagreb School of Medicine, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Zagreb School of Medicine, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Osijek School of Medicine, Osijek, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Osijek School of Medicine, Osijek</wicri:regionArea>
<wicri:noRegion>Osijek</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schnell, Oliver" sort="Schnell, Oliver" uniqKey="Schnell O" first="Oliver" last="Schnell">Oliver Schnell</name>
<affiliation wicri:level="3"><nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Skrha, Jan" sort="Skrha, Jan" uniqKey="Skrha J" first="Jan" last="Škrha">Jan Škrha</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine 3, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Department of Internal Medicine 3, 1st Faculty of Medicine, Charles University, Prague</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
<affiliation wicri:level="1"><nlm:affiliation>Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, APHP, Paris Nord University, Sorbonne Paris Cité, CINFO, CRNH-IdF, Bondy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, APHP, Paris Nord University, Sorbonne Paris Cité, CINFO, CRNH-IdF, Bondy</wicri:regionArea>
<wicri:noRegion>Bondy</wicri:noRegion>
<wicri:noRegion>Bondy</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32690029</idno>
<idno type="pmid">32690029</idno>
<idno type="doi">10.1186/s12933-020-01089-2</idno>
<idno type="pmc">PMC7370631</idno>
<idno type="wicri:Area/Main/Corpus">000891</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000891</idno>
<idno type="wicri:Area/Main/Curation">000891</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000891</idno>
<idno type="wicri:Area/Main/Exploration">000891</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Issues for the management of people with diabetes and COVID-19 in ICU.</title>
<author><name sortKey="Ceriello, Antonio" sort="Ceriello, Antonio" uniqKey="Ceriello A" first="Antonio" last="Ceriello">Antonio Ceriello</name>
<affiliation wicri:level="3"><nlm:affiliation>IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy. antonio.ceriello@hotmail.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Standl, Eberhard" sort="Standl, Eberhard" uniqKey="Standl E" first="Eberhard" last="Standl">Eberhard Standl</name>
<affiliation wicri:level="3"><nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Catrinoiu, Doina" sort="Catrinoiu, Doina" uniqKey="Catrinoiu D" first="Doina" last="Catrinoiu">Doina Catrinoiu</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.</nlm:affiliation>
<country xml:lang="fr">Roumanie</country>
<wicri:regionArea>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta</wicri:regionArea>
<wicri:noRegion>Constanta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Itzhak, Baruch" sort="Itzhak, Baruch" uniqKey="Itzhak B" first="Baruch" last="Itzhak">Baruch Itzhak</name>
<affiliation wicri:level="1"><nlm:affiliation>Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Clalit Health Services and Technion Faculty of Medicine, Haifa</wicri:regionArea>
<wicri:noRegion>Haifa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojsa M" last="Lalic">Nebojsa M. Lalic</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</nlm:affiliation>
<country xml:lang="fr">Serbie</country>
<wicri:regionArea>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade</wicri:regionArea>
<wicri:noRegion>Belgrade</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
<affiliation wicri:level="1"><nlm:affiliation>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Zagreb School of Medicine, Zagreb, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Zagreb School of Medicine, Zagreb</wicri:regionArea>
<wicri:noRegion>Zagreb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>University of Osijek School of Medicine, Osijek, Croatia.</nlm:affiliation>
<country xml:lang="fr">Croatie</country>
<wicri:regionArea>University of Osijek School of Medicine, Osijek</wicri:regionArea>
<wicri:noRegion>Osijek</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schnell, Oliver" sort="Schnell, Oliver" uniqKey="Schnell O" first="Oliver" last="Schnell">Oliver Schnell</name>
<affiliation wicri:level="3"><nlm:affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Skrha, Jan" sort="Skrha, Jan" uniqKey="Skrha J" first="Jan" last="Škrha">Jan Škrha</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine 3, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.</nlm:affiliation>
<country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Department of Internal Medicine 3, 1st Faculty of Medicine, Charles University, Prague</wicri:regionArea>
<placeName><settlement type="city">Prague</settlement>
<region type="région" nuts="2">Bohême centrale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
<affiliation wicri:level="1"><nlm:affiliation>Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, APHP, Paris Nord University, Sorbonne Paris Cité, CINFO, CRNH-IdF, Bondy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, APHP, Paris Nord University, Sorbonne Paris Cité, CINFO, CRNH-IdF, Bondy</wicri:regionArea>
<wicri:noRegion>Bondy</wicri:noRegion>
<wicri:noRegion>Bondy</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Cardiovascular diabetology</title>
<idno type="eISSN">1475-2840</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antihypertensive Agents (therapeutic use)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Biomarkers (blood)</term>
<term>Blood Glucose (drug effects)</term>
<term>Blood Glucose (metabolism)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (mortality)</term>
<term>Coronavirus Infections (therapy)</term>
<term>Coronavirus Infections (virology)</term>
<term>Diabetes Mellitus (blood)</term>
<term>Diabetes Mellitus (diagnosis)</term>
<term>Diabetes Mellitus (drug therapy)</term>
<term>Diabetes Mellitus (mortality)</term>
<term>Dyslipidemias (drug therapy)</term>
<term>Dyslipidemias (mortality)</term>
<term>Host-Pathogen Interactions (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term>
<term>Hypertension (drug therapy)</term>
<term>Hypertension (mortality)</term>
<term>Hypoglycemic Agents (adverse effects)</term>
<term>Hypoglycemic Agents (therapeutic use)</term>
<term>Intensive Care Units (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Pneumonia, Viral (therapy)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Risk Assessment (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antihypertenseurs (usage thérapeutique)</term>
<term>Appréciation des risques (MeSH)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Diabète (diagnostic)</term>
<term>Diabète (mortalité)</term>
<term>Diabète (sang)</term>
<term>Diabète (traitement médicamenteux)</term>
<term>Dyslipidémies (mortalité)</term>
<term>Dyslipidémies (traitement médicamenteux)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Glycémie (effets des médicaments et des substances chimiques)</term>
<term>Glycémie (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Hypertension artérielle (mortalité)</term>
<term>Hypertension artérielle (traitement médicamenteux)</term>
<term>Hypoglycémiants (effets indésirables)</term>
<term>Hypoglycémiants (usage thérapeutique)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (mortalité)</term>
<term>Infections à coronavirus (thérapie)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term>
<term>Interactions hôte-pathogène (MeSH)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (mortalité)</term>
<term>Pneumopathie virale (thérapie)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Unités de soins intensifs (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hypoglycemic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Blood Glucose</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antihypertensive Agents</term>
<term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term>
<term>Hypoglycemic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Diabetes Mellitus</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Diabète</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus</term>
<term>Dyslipidemias</term>
<term>Hypertension</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Glycémie</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Hypoglycémiants</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term>
<term>Diabetes Mellitus</term>
<term>Dyslipidemias</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Diabète</term>
<term>Dyslipidémies</term>
<term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycémie</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète</term>
<term>Dyslipidémies</term>
<term>Hypertension artérielle</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antihypertenseurs</term>
<term>Hypoglycémiants</term>
<term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Intensive Care Units</term>
<term>Pandemics</term>
<term>Risk Assessment</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term>
<term>Facteurs de risque</term>
<term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Pandémies</term>
<term>Résultat thérapeutique</term>
<term>Unités de soins intensifs</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32690029</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>29</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>19</Volume>
<Issue>1</Issue>
<PubDate><Year>2020</Year>
<Month>07</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>Cardiovascular diabetology</Title>
<ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation>
</Journal>
<ArticleTitle>Issues for the management of people with diabetes and COVID-19 in ICU.</ArticleTitle>
<Pagination><MedlinePgn>114</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-020-01089-2</ELocationID>
<Abstract><AbstractText>In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceriello</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">0000-0001-8122-3203</Identifier>
<AffiliationInfo><Affiliation>IRCCS MultiMedica, Via Gaudenzio Fantoli, 16/15, 20138, Milan, Italy. antonio.ceriello@hotmail.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Standl</LastName>
<ForeName>Eberhard</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Catrinoiu</LastName>
<ForeName>Doina</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Clinical Center of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Itzhak</LastName>
<ForeName>Baruch</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lalic</LastName>
<ForeName>Nebojsa M</ForeName>
<Initials>NM</Initials>
<AffiliationInfo><Affiliation>Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rahelic</LastName>
<ForeName>Dario</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Zagreb School of Medicine, Zagreb, Croatia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Osijek School of Medicine, Osijek, Croatia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schnell</LastName>
<ForeName>Oliver</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Forschergruppe Diabetes e.V. at Munich Helmholtz Centre, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Škrha</LastName>
<ForeName>Jan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Internal Medicine 3, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Valensi</LastName>
<ForeName>Paul</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Unit of Endocrinology, Diabetology, Nutrition, Jean Verdier Hospital, APHP, Paris Nord University, Sorbonne Paris Cité, CINFO, CRNH-IdF, Bondy, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>“Diabetes and Cardiovascular Disease (D&CVD)” Study Group of the European Association for the Study of Diabetes (EASD)</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Cardiovasc Diabetol</MedlineTA>
<NlmUniqueID>101147637</NlmUniqueID>
<ISSNLinking>1475-2840</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D050171" MajorTopicYN="N">Dyslipidemias</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Cardiovascular complications</Keyword>
<Keyword MajorTopicYN="Y">Diabetes, Intensive Care Unit</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32690029</ArticleId>
<ArticleId IdType="doi">10.1186/s12933-020-01089-2</ArticleId>
<ArticleId IdType="pii">10.1186/s12933-020-01089-2</ArticleId>
<ArticleId IdType="pmc">PMC7370631</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Endocr Pract. 2012 May-Jun;18(3):363-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22138078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S9-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19179217</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2020 Jun 5;126(12):1671-1681</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Diabetol. 2013 Oct 28;12:156</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24165454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Prev Cardiol. 2019 Dec;26(2_suppl):73-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31766918</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabete Metab. 1990 Mar-Apr;16(2):86-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2196192</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intensive Care. 2020 Feb 7;10(1):17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32034567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Diabetes Endocrinol. 2016 Nov;4(11):890</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27743976</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2019 Aug;47(8):1089-1096</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31206358</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabet Med. 2009 Sep;26(9):872-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19719707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Cardiol. 2020 Mar 27;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219356</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes. 1994 Mar;43(3):430-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8314016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1990 May 1;112(9):678-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2110430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2441-2448</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32356628</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2015 Jun 22;19:270</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26100120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2020 Jun 12;:108270</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32540326</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2020 Jun 22;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32571831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med. 2020 May;46(5):854-887</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2011 Nov;39(11):2440-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21725239</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2005 Nov;28(11):2722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16249546</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacotherapy. 2020 May;40(5):484-486</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32267560</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2020 Apr;162:108132</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32234504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thromb Haemost. 2017 Feb 28;117(3):618-624</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28004063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2018 Aug 2;22(1):182</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30071851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Jul;43(7):1427-1432</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32409501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Metab. 2020 Jun 2;31(6):1068-1077.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32369736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2005 Feb;26(4):328-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15618047</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2019 Dec 6;9(1):18498</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31811218</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2020 Jan 7;41(2):255-323</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31497854</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab Res Rev. 2020 Mar 31;:e3319</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32233013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ageing Res Rev. 2018 Jan;41:1-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29081381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Metabolism. 2020 Jun;107:154216</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Endocrinol Invest. 2020 Jun 8;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32514902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Diabetol. 2018 Aug 18;17(1):116</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30121076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes. 1995 Aug;44(8):924-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7621998</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Diabetes Endocrinol. 2019 Mar;7(3):221-230</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30115599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian J Crit Care Med. 2014 May;18(5):285-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24914256</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2020 Jul 7;142(1):68-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32293910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Herz. 2019 May;44(3):210-217</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30899966</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2372-2374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32302078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2020 Jun;164:108185</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32360710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Sci Technol. 2020 Apr 24;:1932296820915875</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32329372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2020 Jun 4;135(23):2033-2040</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32339221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cardiovasc Prev Rehabil. 2011 Jun;18(3):415-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21450640</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Jul;43(7):1408-1415</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32430456</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ Open Diabetes Res Care. 2020 Apr;8(1):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32345579</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2002 May;25(5):918-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11978691</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Res. 2020 Apr 30;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32352535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Sci Technol. 2011 May 01;5(3):755-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21722591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2017 Apr;38:300-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28063297</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Intensive Care Med. 2019 Nov-Dec;34(11-12):889-896</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30309291</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2020 Apr;162:108118</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32179126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2008 Mar;31(3):556-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18086873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood Press. 2011 Dec;20(6):348-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21675827</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Diabetes Sci Technol. 2019 Jul;13(4):682-690</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30638048</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Explor. 2019 Aug 01;1(8):e0025</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32166267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes. 2008 May;57(5):1349-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18299315</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2020 Apr;162:108137</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32259611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes. 2012 Nov;61(11):2993-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22891214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Pharmacol. 2015 Feb 1;93(3):343-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25482567</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Diabetol. 2019 Jan 11;18(1):4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30634972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetologia. 2020 Aug;63(8):1500-1515</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32472191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32311448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2020 May;163:108151</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32305399</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2020 Jun;43(6):1200-1208</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32161049</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Jun 13;395(10240):1820</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32511943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Res Clin Pract. 2016 May;115:24-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27242119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Diabetol. 2019 Nov 9;18(1):147</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31706305</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cardiovasc Diabetol. 2020 Jun 11;19(1):76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32527257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetologia. 1993 Nov;36(11):1119-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8270125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Metab. 2020 May 21;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32447102</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Croatie</li>
<li>France</li>
<li>Israël</li>
<li>Italie</li>
<li>Roumanie</li>
<li>République tchèque</li>
<li>Serbie</li>
</country>
<region><li>Bavière</li>
<li>Bohême centrale</li>
<li>District de Haute-Bavière</li>
<li>Lombardie</li>
</region>
<settlement><li>Milan</li>
<li>Munich</li>
<li>Prague</li>
</settlement>
</list>
<tree><country name="Italie"><region name="Lombardie"><name sortKey="Ceriello, Antonio" sort="Ceriello, Antonio" uniqKey="Ceriello A" first="Antonio" last="Ceriello">Antonio Ceriello</name>
</region>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Standl, Eberhard" sort="Standl, Eberhard" uniqKey="Standl E" first="Eberhard" last="Standl">Eberhard Standl</name>
</region>
<name sortKey="Schnell, Oliver" sort="Schnell, Oliver" uniqKey="Schnell O" first="Oliver" last="Schnell">Oliver Schnell</name>
</country>
<country name="Roumanie"><noRegion><name sortKey="Catrinoiu, Doina" sort="Catrinoiu, Doina" uniqKey="Catrinoiu D" first="Doina" last="Catrinoiu">Doina Catrinoiu</name>
</noRegion>
</country>
<country name="Israël"><noRegion><name sortKey="Itzhak, Baruch" sort="Itzhak, Baruch" uniqKey="Itzhak B" first="Baruch" last="Itzhak">Baruch Itzhak</name>
</noRegion>
</country>
<country name="Serbie"><noRegion><name sortKey="Lalic, Nebojsa M" sort="Lalic, Nebojsa M" uniqKey="Lalic N" first="Nebojsa M" last="Lalic">Nebojsa M. Lalic</name>
</noRegion>
</country>
<country name="Croatie"><noRegion><name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
</noRegion>
<name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
<name sortKey="Rahelic, Dario" sort="Rahelic, Dario" uniqKey="Rahelic D" first="Dario" last="Rahelic">Dario Rahelic</name>
</country>
<country name="République tchèque"><region name="Bohême centrale"><name sortKey="Skrha, Jan" sort="Skrha, Jan" uniqKey="Skrha J" first="Jan" last="Škrha">Jan Škrha</name>
</region>
</country>
<country name="France"><noRegion><name sortKey="Valensi, Paul" sort="Valensi, Paul" uniqKey="Valensi P" first="Paul" last="Valensi">Paul Valensi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C18 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C18 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32690029
   |texte=   Issues for the management of people with diabetes and COVID-19 in ICU.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32690029" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Issues for the management of people with diabetes and COVID-19 in ICU.

Issues for the management of people with diabetes and COVID-19 in ICU.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki